DR. DAVID M WEINER, M.D.
Neurology at Arbor Dr, San Diego, CA
License number
California A64132
Category
Neurology
Type
Neurology
Address
Address
200 WEST Arbor Dr, San Diego, CA 92103
Phone
(858) 657-8540
(858) 657-8557 (Fax)
(858) 657-8557 (Fax)
Personal information
See more information about DAVID M WEINER at radaris.comName
Address
Phone
500 W Harbor Dr UNIT 1213, San Diego, CA 92101
505 Vidal Dr, San Francisco, CA 94132
5455 Wayman St, Riverside, CA 92504
5760 Ensign Ave, North Hollywood, CA 91601
5282 Hamer Ln, Placentia, CA 92870
Professional information
Physician Scientist
Location:
Greater San Diego Area
Industry:
Biotechnology
Work:
EMD Serono
2010 - 2011
-
Vice President Neurology Clinical Development
Merck Serono
2008 - 2011
-
Head of Early Cinical Develpment
EMD Serono
2007 - 2010
-
Senior Medical Director
ACADIA Pharmaceuticals
1997 - 2006
-
Medical Director
ACADIA Pharmaceuticals
1997 - 2006
-
Head of Target Validation
David Weiner
Location:
Greater San Diego Area
Industry:
Biotechnology
Skills:
Genomics, High Throughput Screening, Biotechnology, Biochemistry, R&D, Molecular Biology, Protein Purification, Lifesciences, Technology Transfer, Biofuels, Protein Chemistry, Purification, Drug Discovery
Shop Foreman At La Jolla Playhouse/Ucsd
Position:
Shop Foreman at La Jolla Playhouse/UCSD
Location:
Greater San Diego Area
Industry:
Design
Work:
La Jolla Playhouse/UCSD
-
Shop Foreman
Selective Serotonin 2A/2C Receptor Inverse Agonists As Therapeutics For Neurodegenerative Diseases
US Patent:
8377959, Feb 19, 2013
Filed:
Jun 29, 2012
Appl. No.:
13/539011
Inventors:
David M. Weiner - San Diego CA, US
Robert E. Davis - San Diego CA, US
Mark R. Brann - Rye NH, US
Carl-Magnus A. Andersson - Hjärup, SE
Allan K. Uldam - Vaerloese, DK
Robert E. Davis - San Diego CA, US
Mark R. Brann - Rye NH, US
Carl-Magnus A. Andersson - Hjärup, SE
Allan K. Uldam - Vaerloese, DK
Assignee:
ACADIA Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/47, A61K 31/445
US Classification:
514310, 514317
Abstract:
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
G-Protein Coupled Receptors High-Throughput Functional Assay
US Patent:
2008028, Nov 13, 2008
Filed:
May 12, 2008
Appl. No.:
12/119119
Inventors:
Ethan S. Burstein - San Diego CA, US
Fabrice Piu - San Diego CA, US
Jian-Nong Ma - San Diego CA, US
Jacques Weissman - Carlsbad CA, US
David M. Weiner - San Diego CA, US
Audra L. Scully - Carlsbad CA, US
Norman Nash - San Diego CA, US
Tracy Spalding - San Diego CA, US
Erika Currier - San Diego CA, US
Fabrice Piu - San Diego CA, US
Jian-Nong Ma - San Diego CA, US
Jacques Weissman - Carlsbad CA, US
David M. Weiner - San Diego CA, US
Audra L. Scully - Carlsbad CA, US
Norman Nash - San Diego CA, US
Tracy Spalding - San Diego CA, US
Erika Currier - San Diego CA, US
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435 6, 435 72
Abstract:
Disclosed herein are methods for enabling or improving functional assays of G-protein coupled receptors through the use of co-expression of helper genes. In some cases, chimeras linking the regulatory domain of the rap1B protein to the effector region of the ras oncogene are used in conduction with existing functional assays for cellular proliferation. Furthermore, overexpression of other genes can further augment the enabling properties of ras/rap chimeras.
Use Of N-Desmethylclozapine To Treat Human Neuropsychia Tric Disease
US Patent:
2006019, Sep 7, 2006
Filed:
May 3, 2006
Appl. No.:
11/417069
Inventors:
David Weiner - San Diego CA, US
Mark Brann - Del Mar CA, US
Mark Brann - Del Mar CA, US
International Classification:
A61K 31/551
US Classification:
514220000
Abstract:
Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease.
Use Of N-Desmethylclozapine To Treat Human Neuropsychiatric Disease
US Patent:
2004022, Nov 11, 2004
Filed:
Jan 21, 2004
Appl. No.:
10/761787
Inventors:
David Weiner - San Diego CA, US
Mark Brann - Del Mar CA, US
Mark Brann - Del Mar CA, US
International Classification:
A61K031/551
US Classification:
514/220000
Abstract:
Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease.
G-Protein Coupled Receptors High-Throughput Functional Assay
US Patent:
2005012, Jun 9, 2005
Filed:
Nov 2, 2004
Appl. No.:
10/980885
Inventors:
Ethan Burstein - San Diego CA, US
Fabrice Piu - San Diego CA, US
Jian-Nong Ma - San Diego CA, US
Jacques Weissman - Carlsbad CA, US
David Weiner - San Diego CA, US
Audra Scully - Carlsbad CA, US
Norman Nash - San Diego CA, US
Tracy Spalding - San Diego CA, US
Erika Currier - San Diego CA, US
Fabrice Piu - San Diego CA, US
Jian-Nong Ma - San Diego CA, US
Jacques Weissman - Carlsbad CA, US
David Weiner - San Diego CA, US
Audra Scully - Carlsbad CA, US
Norman Nash - San Diego CA, US
Tracy Spalding - San Diego CA, US
Erika Currier - San Diego CA, US
International Classification:
C12Q001/68, C07H021/04, C07K014/705, C12N015/85
US Classification:
435006000, 435069100, 435455000, 435320100, 435325000, 530350000, 536023500
Abstract:
Disclosed herein are methods for enabling or improving functional assays of G-protein coupled receptors through the use of co-expression of helper genes. In some cases, chimeras linking the regulatory domain of the rap1B protein to the effector region of the ras oncogene are used in conjuction with existing functional assays for cellular proliferation. Furthermore, overexpression of other genes can further augment the enabling properties of ras/rap chimeras.
Methods Of Identifying Inverse Agonists Of The Serotonin 2A Receptor
US Patent:
2005014, Jul 7, 2005
Filed:
Mar 4, 2005
Appl. No.:
11/073313
Inventors:
David Weiner - San Diego CA, US
Mark Brann - Del Mar CA, US
Mark Brann - Del Mar CA, US
International Classification:
C12Q001/68, A61K038/00
US Classification:
435006000, 514002000
Abstract:
The present invention relates to a method of identifying compounds which act as inverse agonists of the 5-HT2A receptor, the method comprising contacting a constitutively active 5-HT2A receptor with at least one test compound and determining any decrease in the level of basal activity of the receptor so as to identify a test compound which is an inverse agonist of the 5-HT2A receptor. Such inverse agonists may be used in the treatment of schizophrenia and related psychoses.
Use Of N-Desmethylclozapine To Treat Human Neuropsychiatric Disease
US Patent:
2006019, Aug 31, 2006
Filed:
May 3, 2006
Appl. No.:
11/416565
Inventors:
David Weiner - San Diego CA, US
Mark Brann - Del Mar CA, US
Mark Brann - Del Mar CA, US
International Classification:
A61K 31/4743
US Classification:
514301000
Abstract:
Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease.